Axsome Therapeutics, Inc. company information, Employees & Contact Information

Axsome Therapeutics to Participate in Upcoming Investor Conferences Yahoo Finance

Axsome Therapeutics (NASDAQ: AXSM) to join Truist, Guggenheim and UBS conferences in November Stock Titan

Q3 2025 Results Nov 3: Axsome Therapeutics to Report Results and Host 8:00 AM ET Conference Call; Webcast Stock Titan

1 in 5 U.S. adults affected — Axsome Recognizes Mental Illness Awareness Week and shares NAMI resources Stock Titan

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community Yahoo Finance

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month Yahoo Finance

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone Yahoo Finance

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 Yahoo Finance

Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia Yahoo Finance

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month Yahoo Finance

Axsome Therapeutics Hosts R&D Day to Present Comprehensive Data on CNS Pipeline Targeting Alzheimer’s Disease, Depression, Narcolepsy, Fibromyalgia, ADHD, and Smoking Cessation Nasdaq

Major CNS Biotech Axsome Therapeutics Set for 6 High-Profile Healthcare Conferences in September 2025 Stock Titan

Axsome Therapeutics Highlights Key Presentations at Psych Congress 2025 on CNS Disorders and Innovative Treatment Approaches Quiver Quantitative

Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults Yahoo Finance

Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) Yahoo Finance

Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting Yahoo Finance

Axsome Therapeutics R&D Day: Key Opinion Leaders to Reveal Next-Gen CNS Treatment Innovations Stock Titan

Major CNS Breakthroughs: Axsome Presents Data on Depression, Alzheimer's, and Sleep Disorders Pipeline Stock Titan

Axsome Earnings: Record $150M Revenue as Depression Drug AUVELITY Sales Soar 84%, Pipeline Expands Stock Titan

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission Yahoo Finance

Axsome Therapeutics Secures $570 Million Financing Facility with Blackstone, Retires Previous Loan Nasdaq

Axsome Therapeutics Enters Settlement with Hetero Labs to Resolve SUNOSI® Patent Litigation Nasdaq

Axsome Celebrates New CNS Drug Launch with NASDAQ Bell Ringing, Unveils Brain Health Pipeline Stock Titan

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Yahoo Finance

Axsome Reveals New Phase 3 Data for 6 Major Brain Disorders: Expert Panel Discusses Breakthrough Treatments Stock Titan

Axsome Wins 17 Years of Market Exclusivity for SUNOSI in Patent Settlement with Hetero Stock Titan

FDA Rejects Axsome's Fibromyalgia Drug AXS-14: What's Next for 17M Patient Market Stock Titan

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults Yahoo Finance

Axsome Therapeutics to Present SYMBRAVO® Clinical Data at the 67th Annual Scientific Meeting of the American Headache Society Nasdaq

Axsome Unveils Phase 3 Narcolepsy Trial Results Among 7 Major Presentations at SLEEP 2025 Stock Titan

Axsome Therapeutics Highlights Seven Presentations on AXS-12 and Solriamfetol at SLEEP 2025 Conference Nasdaq

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone Stock Titan

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 The Manila Times

Axsome Therapeutics Partners With Migraine Association to Help 40 Million US Patients Find Better Days Stock Titan

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors Yahoo Finance

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation Yahoo Finance

Revolutionary Migraine Drug SYMBRAVO Now Available: Fast-Acting Relief Targets Multiple Pain Pathways Stock Titan

U.S. FDA Approves Axsome Therapeutics’ SYMBRAVO™ (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults MultiVu

Axsome Therapeutics Receives FDA Approval for SYMBRAVO, a Novel Acute Treatment for Migraine Pain Relief Quiver Quantitative

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Yahoo Finance

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 Yahoo Finance

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine Yahoo Finance

Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week Yahoo Finance

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20 Stock Titan

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors citybiz

Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe Stock Titan

Axsome Therapeutics Announces FDA Approval of AUVELITY(TM) MultiVu

Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine PR Newswire

Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea PR Newswire

Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform Veeva